Skip to main content
SpringerLink
Log in

Maligne Tumoren des Ovars

  • Chapter
  • First Online:
Therapiehandbuch Gynäkologie und Geburtshilfe

  • 4859 Accesses

Zusammenfassung

Hierzu zählen Borderline-Tumoren, Ovarialkarzinome, Keimstrangstromatumoren und Keimzelltumoren. 90 % sind epitheliale Tumoren. Die Therapie besteht bei Karzinomen in den frühen Stadien FIGO IA‒IIA in der Operation mit Hysterektomie, beidseitiger Adnektomie, Omentektomie, peritonealem Staging mit Probeentnahmen, pelviner und paraaortaler Lymphonodektomie und der postoperativen platinhaltigen Chemotherapie bei gering differenzierten Tumoren oder Stadium FIGO IC. In den fortgeschrittenen Stadien mit disseminierter Tumorausbreitung im Abdomen werden eine radikale Debulking-Operation mit dem Ziel der kompletten Tumorresektion und die postoperative Chemotherapie mit Carboplatin und Paclitaxel durchgeführt. Bevacizumab kann ab Stadium FIGO III anboten werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483

    Article  CAS  Google Scholar 

  • du Bois A et al (2009a) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115(6):1234–1244

    Article  Google Scholar 

  • du Bois A, Ewald-Riegler N, du Bois O, Harter P (2009b) Borderline tumors of the ovary – a systematic review. Geburtsh Frauenheilkd 69(9):807–833

    Article  Google Scholar 

  • du Bois A, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Jensen P, Selle F, Guyon F, Pomel C, Lecuru F, Zang R, Avall-Lunqvist E, Kim JW, Ponce J, Raspagliesi F, Ghaem-Maghami S, Reinthaller A, Harter P, PI, Sehouli J (2017) Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: the interim analysis of AGO DESKTOP III / ENGOT ov20. J Clin Oncol 35 (suppl; abstr 5501)

    Google Scholar 

  • González-Martin A et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa1910962

  • Harter P, Hauke J, Heitz F et al (2016) Incidence of germline mutations in risk genes including BRCA1/2 in consecutive ovarial cancer (OC) patients (AGO TR-1). J Clin Oncol 2016:34

    Google Scholar 

  • Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspaglioni F, Lampe B, Landoni F, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Wagner UAG, duBois A (2017) LION: Lymphadenectomy in ovarian neoplasm – a prospective randomized AGO study group led gynecologic intergroup trial. J Clin Oncol 35 (suppl;abstr 5500)

    Google Scholar 

  • Leitlinienprogramm Onkologie (DGK, DGGG, AWMF) (2017) S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren (Langversion). Version 2.0 – Oktober 2017. AWMF-Registernummer: 032/035OL. www.awmf.org/leitlinien/detail/II/032-035OL.html

  • McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6

    Article  CAS  Google Scholar 

  • Meinhold-Heerlein I1, Fotopoulou C2, Harter S2, Kurzeder C2, Mustea A2, Wimberger S2, Hauptmann S2, Sehouli J (2016) The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch Gynecol Obstet 293(4):695–700

    Google Scholar 

  • Mirza MR et al (2016) Niraparib Mainenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer. N Engl J Med 375:2154–2164

    Article  CAS  Google Scholar 

  • Moore K et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379:2495–2505. https://doi.org/10.1056/NEJMoa1810858

  • National Cancer Institute. Ovarian germ cell tumor. http://cancer.gov/

  • Ray-Coquard IL et al (2019) Phase III PAOLA-1/ENGOT-ov25: Maintenance olaparib with bevacizumab in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapie and Bevacizumab as standard of care. ESMO, abstract LBA2

    Google Scholar 

  • Winter-Roach BA, Kitchener BA, Dickenson HO (2009) Adjuvant post-surgery chemotherapy for early stage epitheliel ovarian cancer. Cochrane Database Syst Rev 2009(1):CD004706

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Gynäkologie, Universitätsklnikum Hamburg Eppendorf, Hamburg, Deutschland

    Barbara Schmalfeldt

Authors
  1. Barbara Schmalfeldt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barbara Schmalfeldt .

Editor information

Editors and Affiliations

  1. Fürst-Stirum-Klinik Bruchsal Frauenklinik, Bruchsal, Germany

    Jürgen Wacker

  2. Praxisklinik am Rosengarten, Mannheim, Germany

    Martin Sillem

  3. Praxisklinik am Rosengarten, Mannheim, Germany

    Gunther Bastert

  4. Frauenklinik, Universitätsklinikum Erlangen-Nürnberg Frauenklinik, Erlangen, Germany

    Matthias W. Beckmann

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Schmalfeldt, B. (2020). Maligne Tumoren des Ovars. In: Wacker, J., Sillem, M., Bastert, G., Beckmann, M. (eds) Therapiehandbuch Gynäkologie und Geburtshilfe. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-59809-2_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-59809-2_33

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-59808-5

  • Online ISBN: 978-3-662-59809-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation